Edward Nash

Stock Analyst at Canaccord Genuity

(4.29)
# 379
Out of 4,893 analysts
82
Total ratings
49.3%
Success rate
19.24%
Average return

Stocks Rated by Edward Nash

Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $104.85
Upside: +2.05%
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394$420
Current: $314.64
Upside: +33.49%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $22.68
Upside: +182.19%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45$47
Current: $16.49
Upside: +185.02%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130$142
Current: $72.01
Upside: +97.19%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.66
Upside: +1,263.02%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.40
Upside: +185.71%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56$73
Current: $52.00
Upside: +40.38%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $38.57
Upside: +130.75%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15$14
Current: $2.84
Upside: +392.96%
Maintains: Buy
Price Target: $6$8
Current: $1.36
Upside: +488.24%
Maintains: Buy
Price Target: $12$20
Current: $3.38
Upside: +491.72%
Assumes: Hold
Price Target: $8
Current: $3.15
Upside: +153.97%
Maintains: Buy
Price Target: $16$17
Current: $5.25
Upside: +224.12%
Maintains: Hold
Price Target: $3$2
Current: $2.16
Upside: -7.41%
Downgrades: Hold
Price Target: $900$180
Current: $2.03
Upside: +8,767.00%
Maintains: Buy
Price Target: $80$82
Current: $31.04
Upside: +164.22%
Maintains: Hold
Price Target: $120$80
Current: $2.72
Upside: +2,841.18%
Initiates: Buy
Price Target: $48
Current: $14.90
Upside: +222.15%
Initiates: Buy
Price Target: $650
Current: $5.85
Upside: +11,011.11%